Groundbreaking diagnostic method promises earlier detection and intervention
A team of scientists has developed a pioneering brain scanning technique that could transform the early diagnosis of Alzheimer’s disease, identifying signs of neurodegeneration long before symptoms emerge. The innovation, known as cortical disarray measurement (CDM), uses advanced MRI analysis to detect microscopic changes in the brain’s cortex, well ahead of current diagnostic capabilities.
A leap forward in dementia detection
Traditionally, Alzheimer’s and other forms of dementia are diagnosed through a combination of memory questionnaires and MRI imaging, often once significant damage has already occurred. This delay limits the scope for early intervention, when treatment may be most effective.
With the new method, clinicians can examine disruptions in the brain’s cortical structure, particularly in areas responsible for memory, language, and decision-making, offering a more precise and earlier window into the disease process.
In a statement, Oxford Brain Diagnostics, the British company behind the innovation, explained, “Our sophisticated diffusion analysis is based on a deep understanding of neuropathology, and the correlations between microscopic brain data and MRI analysis.”
How the technology works
According to the developers, CDM is a fully cloud-native, non-invasive diagnostic platform designed to track brain changes throughout adulthood. Its key features include:
- Compatibility with both 1.5T and 3T clinical MRI scanners
- Generation of images and numerical data, benchmarked against a normative population using percentiles
- Delivery of detailed insights into subtle cortical disruptions
The technology has already received “breakthrough device” designation from the U.S. Food and Drug Administration (FDA), allowing for expedited development and regulatory review.
Behind the company are two leading figures in neuroscience—Dr. Steven Chance, formerly an associate professor at Oxford University, and Professor Mark Jenkinson, an expert in brain imaging. The venture is funded by the Oxford Technology & Innovations Fund and UK investment firm BGF.
AI-powered insights from the U.S.
In a parallel development, researchers at Mass General Brigham unveiled an artificial intelligence (AI) tool last month that analyzes sleep-related brain activity to predict cognitive decline. Using electroencephalography (EEG), the tool was able to identify 85% of individuals who later developed cognitive impairment, with an overall accuracy of 77%.
A global challenge with growing urgency
According to the World Health Organization, approximately 55 million people worldwide currently live with dementia—a number expected to rise sharply as populations age. Recent studies suggest that behavioral and physiological changes may begin long before cognitive decline becomes noticeable. Tools like CDM and AI-based prediction models could open new doors for pre-symptomatic diagnosis and timely treatment.
With Alzheimer’s research now moving toward earlier detection and more personalized interventions, these technological breakthroughs represent a crucial turning point in the fight against one of the world’s most pressing neurological health challenges.
